Promethera® is committed to develop life-changing new cell therapies for patients suffering from serious liver diseases.
As an innovator in the emerging field of cell-based medicines, Promethera® is driven by the ambition of creating a diverse portfolio of drug candidates with partners and on our own account. This vision has attracted a broad range of European and Asian institutional and corporate investors throughout the Company’s development steps as a privately-held organization.
* Essentially HNWI and private investors
Promethera® has garnered the support of important investors that operate globally and spread accross three continents – Europe, North America and Asia.
Since inception, Promethera® has raised EUR 120 million in equity and semi-equity, not including non-dilutive support from the Walloon region of Belgium through grants and recoverable cash advances.
- Prof. Etienne Sokal
Current Investors overview
- Hopp Family (Weinheim GmbH & Co KG)
- Vesalius Biocapital (Lead investor)
- SMS Investment
- Boehringer Ingelheim Venture Fund
- MGI Global Fund (Mitsui)
- Cell Innovation Partners, L.P. (CIP)
- Mitsubishi UFJ Capital
- Beyond Next Ventures
- LifeLiver Co., Ltd.
- Co-High Investment
- Medipal Corporation
- Ci :Z Investment
- SONY Group by IGV
- KIP Re-up Fund
- Pegasus Tech Ventures